Your browser does not fully support modern features. Please upgrade for a smoother experience.
Encyclopedia Insights
More  >>
Ongoing
Encyclopedia MDPI is thrilled to announce significant enhancements to its Academic Video Service, which aim to improve its quality, accessibility, and functionality. Since its launch, our video service has enabled numerous scholars to present their research in a dynamic and visually engaging format, greatly enhancing its visibility and impact. Due to the overwhelmingly positive reception this service has received, we have reached a point where the number of orders we are receiving exceeds our current capacity. In order to maintain the quality of these videos and continue optimizing the service, we have made the decision to introduce a fee. However, to ensure that this service is still a cost-effective option, we have set our prices significantly below the market average. 1. Highlights of the Upgrades to the Service Although the service will now be fee-based, we are committed to providing even more professional and comprehensive support, including the following: One-on-one video production guidance Personalized assistance to ensure your needs are fully met. Scriptwriting and English editing Expertly crafted narratives and professional English editing to ensure your research is presented clearly, accurately, and with impact. High-quality animations Visually engaging animations are created to simplify complex research and captivate your audience. Whiteboard Animations: Clean and minimalist, using hand-drawn illustrations to explain ideas step-by-step. Motion Graphics (MG) Animations: Cartoon Style: Bright, colorful, and approachable, ideal for making technical or scientific content more accessible and engaging. Hand-Drawn Style: Unique and artistic, adding a personal touch to your research while maintaining clarity and professionalism. Customized infographics (optional) We can also create tailored infographics to visually summarize key data or findings, enhancing the clarity and appeal of your video. Native voiceover Native speakers provide voiceovers to enhance the accessibility and reach of your research. Multiple rounds of revision To ensure your video accurately represents your work. Social media promotion Expanding your research's visibility and impact. 2. Why Choose Us? The Proven Impact of Video Abstracts Research shows that a well-crafted video abstract can significantly enhance the visibility and impact of your work. It has been shown to do the following: Increase paper views by 120% (Source: 10.1007/ s11192-019-03108-w) Boost citations by 20% (Source: Wiley Online Library) Improve journal rankings by 33% (Source: Research Square) Raise Altmetrics scores by 140% (Source: Research Square) Our Expertise in Academic Research Backed by MDPI, our experienced production team combines deep academic knowledge with creative excellence. We understand the nuances of scholarly communication and ensure that every frame accurately conveys the value of your research, meeting the highest standards of quality and precision. Collaborations with SCI Journals We have partnered with over 60 SCI journals to create exclusive video series, enhancing the dissemination and impact of published research. For example, our collaborations with Entropy, Remote Sensing, Nanomaterials , Animals , Nutrients, Foods , Sustainability, Cancers, etc., have helped authors achieve greater visibility and recognition for their work. Global visibility The videos are linked to your paper's DOI for maximum exposure. Available Video Services and Their Pricing Video Abstract (up to 5 minutes long): Summarizes the key findings, methodology, and significance of your research paper. Regular Price: 600 CHF Short Take (up to 2 minutes long): Uses original animations to explain the specific aspects of your research. Regular Price: 500 CHF Scholar Interview: A face-to-face discussion offering deeper insights into your publication. Regular Price: 400 CHF Scholar Profile: A brief overview of a scholar’s career, highlighting education, research focus, and key achievements. Regular Price: 500 CHF 3. Video Production Service If you want to see some examples of our videos, please visit https://encyclopedia.pub/video. If you would like to apply for the video service, please click https://encyclopedia.pub/video_service. 4. Others If you have any other questions, please contact office@encyclopedia.pub.
Announcement 14 Apr 2026
As modern reading habits shift toward rapid digital consumption and AI-assisted parsing, relying solely on static PDFs risks burying groundbreaking research in a digital crypt. Every single day, thousands of brilliant, groundbreaking papers are uploaded to academic repositories. Weeks, months, and sometimes years of exhaustive lab work, funding applications, and intellectual energy are condensed into a highly structured, peer-reviewed document. Then, for the vast majority of these papers, the trajectory flatlines. They are downloaded as a standard PDF, skimmed for a few seconds, and filed away into the silent crypts of reference managers, never to be opened again. The hard truth is that the traditional academic paper was designed for the printing press, not the smartphone, the modern web browser, or the AI answer engine. We are still communicating 21st-century science using a 19th-century format. In an era where information velocity is measured in seconds, relying solely on an ossified, 20-page static PDF to convey your life's work isn't just an outdated habit—it is a massive career bottleneck. If we want our research to actually change the world, or even just get cited, the way we communicate science must fundamentally evolve. 1. The Shifting Anatomy of Scholarly Attention We need to be honest about how we, as researchers, actually consume the literature today. We do not read linearly from abstract to conclusion. Drowning in cognitive overload and constrained by shrinking schedules, modern academics browse, filter, parse, and prompt. Increasingly, we rely on artificial intelligence tools and answer engines to summarize key findings, extract methodologies, and synthesize data before we ever commit to reading a full text. If your paper exists only as an unyielding wall of dense, academic prose trapped in a PDF—a format that is notoriously hostile to machine reading—you are making it incredibly difficult for the digital ecosystem to discover your work. A striking gap has emerged between passive publishing and active, multi-channel engagement. Depositing a paper in a journal repository and expecting the scientific community to discover it by chance is an uphill battle against an unforgiving algorithm (Figure 1). Figure 1. The research attention gap. A comparative projection of longitudinal reach showing traditional static publishing versus modern multi-channel digital engagement (conceptual model derived from aggregated institutional repository download analytics). As Figure 1 visually illustrates, multi-channel visibility acts as a massive force multiplier for full-text downloads. When you wrap a core paper in a dynamic digital ecosystem, you are not "dumbing down" the science; you are building an explicit, frictionless pathway that guides readers directly to your data. 2. Beyond the Impact Factor: The Real-Time Attention Economy For decades, the standard metric of academic success has been the journal Impact Factor. We have outsourced our professional worth to a single, lagging index. But waiting two to three years for a traditional citation to show up in a database is an archaic way to build a scientific reputation or demonstrate societal value to funding bodies. The digital era has democratized impact through alternative metrics—such as Altmetrics and PlumX—which track the real-time footprint of a paper across mainstream news, policy documents, authoritative blogs, Wikipedia, and social platforms. This data matters because funding agencies and tenure committees are rapidly shifting their gaze toward verifiable, immediate societal impact (Figure 2). Figure 2. How the digital era tracks real-time impact. The official Altimetric statistical weighting matrix, showcasing the value assigned to non-traditional scholarly discussions. Look closely at the data in Figure 2. A single mention in a mainstream news outlet, an inclusion in a public policy brief, or a highly shared thread by an authoritative academic moves the needle of your real-time research footprint far faster than a standard repository upload. Digital communication is no longer an optional hobby for eccentric scientists; it is actively indexed, mathematically weighted, and structurally embedded into how institutions measure visibility. 3. The 3-Tier Digital Dissemination Strategy Transitioning into digital-first science communication does not mean you need to sacrifice your lab time to become a full-time content creator. It requires a strategic, highly efficient toolkit designed to layer over your existing publications. 3.1. The Micro-Abstract as an Algorithmic Hook The moment your paper is accepted, translate your abstract into a high-impact digital thread. Strip away the heavy jargon and focus purely on three core questions: What was the problem? What did you find? Why does it matter to the world outside your lab? Publish this on professional networks like LinkedIn or X (formerly Twitter). Think of it as a digital front door to your paper. You are giving both human readers and search algorithms the exact keywords they need to find you. 3.2. Frictionless Accessibility via the Open Access Pipeline Never let your paper live exclusively behind an institutional paywall if you can legally avoid it. Maximize the use of green open-access repositories, pre-print servers, and academic research networks. If a policymaker, a science journalist, or a peer from an underfunded institution clicks your link and hits a $40 paywall, your research effectively ceases to exist for them. Remove the friction. 3.3. High-Density Encoding with Visuals and Video Human brains process visuals thousands of times faster than text. Accompany your paper with a single visual abstract or a clean infographic that highlights your primary chart. More importantly, embrace the video abstract. This does not require a cinematic budget. Record a raw, 60-second Zoom screen-share of your paper’s definitive figure with your webcam turned on. Explain the data exactly how you would to a colleague standing next to you at a conference poster session. Modern digital algorithms heavily prioritize authentic, face-to-camera human communication over polished, detached corporate marketing. A 60-second video can easily earn more engagement in a single afternoon than a static text abstract will accumulate over an entire semester. 4. Reclaiming the Power of Your Output The traditional academic infrastructure has conditioned us to believe that our job ends the moment the "Submit" button turns into an "Accepted" notification. It doesn't. In a crowded, hyper-accelerated digital landscape, taking control of how your research is communicated is not an act of vanity—it is an act of professional survival. We must stop treating public engagement as an administrative chore or a secondary distraction. By transforming our static findings into dynamic, discoverable multimedia assets, we bridge the gap between isolated laboratories and the global community. Let your data live outside the margins of an 8.5x11-inch PDF. Evolve your communication style, break through the digital noise, and give your science the attention it genuinely deserves. Biography Dr. Akeem Adeyemi Oladipo is a Research Professor of Chemistry at Eastern Mediterranean University (Cyprus), where he heads the SMART LAB (Electro-Bio-Environmental & Energy Technologies). Recognized globally among the Top 2% of Scientists by Stanford University and Elsevier, his pioneering research sits at the critical nexus of nanotechnology, advanced materials, and AI-driven materials discovery. Refusing to let his findings languish in academic repositories, Dr. Oladipo is an active deep-tech entrepreneur and the founder of multiple commercial ventures, including TracePulse, Adsoora, and ReduOXLab. Through these startups, he actively translates complex laboratory breakthroughs—such as high-performance nanofluids and advanced environmental remediation strategies—into scalable, industry-ready technologies. A highly prolific author and Editorial Board Member, he is deeply passionate about bridging the gap between isolated laboratory data and high-visibility, real-world sustainable solutions.
Blog 15 Jul 2026
Modern diabetes management is moving from glucose-centred care to precision cardiometabolic risk stratification. Because patients who share the same HbA1c can carry very different cardiovascular, renal, hepatic and metabolic risks, treatment is increasingly guided by clinical phenotype rather than by glucose alone. Drawing on the evidence for GLP-1 receptor agonists and SGLT2 inhibitors, this outcome-centred approach tailors therapy to each patient's dominant risk and targets the long-term outcomes that matter most beyond glycaemic control. 1. The Era of Glucose-Centred Diabetes Care Is Over For many years, glycated haemoglobin (HbA1c) represented the cornerstone of diabetes management. Achieving glycaemic targets was rightly considered the primary therapeutic goal, because lowering glucose reduces the risk of microvascular complications such as retinopathy, nephropathy and neuropathy. The UK Prospective Diabetes Study established this microvascular benefit decades ago, yet its macrovascular signal emerged only slowly, a reminder that glucose lowering protects small vessels far more readily than it protects the heart. Glucose control alone never fully explained why some patients deteriorated despite excellent HbA1c values, while others remained stable. Cardiovascular outcome trials and contemporary guidelines have since transformed our understanding of the disease. Today, type 2 diabetes is recognised as a complex cardiometabolic disorder in which cardiovascular disease, chronic kidney disease, obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure frequently coexist and strongly influence prognosis [1–3]. 2. Every Patient Has a Different Cardiometabolic Profile Two patients may present with an identical HbA1c value while requiring completely different therapeutic strategies. A younger individual living with obesity and MASLD has different priorities from an older patient with chronic kidney disease and a previous myocardial infarction. For this reason, treatment decisions increasingly rely on comprehensive clinical phenotyping rather than on isolated laboratory parameters. Cardiovascular risk, renal function, albuminuria, heart failure, body weight, liver involvement, frailty and life expectancy should all contribute to therapeutic selection. Modern guidelines reflect this by suggesting that the first therapeutic question is no longer simply how high the glucose is, but which organs are most at risk. The same diagnosis, in other words, can describe profoundly different patients, and each profile points towards a different first choice of therapy [1,2]. 3. Precision Medicine Has Already Entered Routine Care Precision medicine is often associated with genomics or advanced molecular profiling. In type 2 diabetes, however, it is already part of everyday practice. The landmark cardiovascular outcome trials made this concrete. In EMPA-REG OUTCOME, the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin reduced cardiovascular death and heart failure hospitalisation in patients with established cardiovascular disease [4]. In LEADER and SUSTAIN-6, the glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide and semaglutide reduced major cardiovascular events in high-risk patients [5,6]. Importantly, these were not merely glucose-lowering effects: the benefits appeared too early and too consistently to be explained by HbA1c reduction alone, pointing instead to direct cardiac and renal actions. Selecting a GLP-1 receptor agonist when obesity and atherosclerotic risk predominate, or an SGLT2 inhibitor when heart failure or chronic kidney disease is present, is precision medicine in action. The objective is simple: the right treatment, for the right patient, at the right time. This shift from glucose-centred to outcome-centred medicine is summarised in Figure 1 [1–6]. Figure 1. From traditional glucose-centred diabetes care to precision cardiometabolic medicine. ASCVD: atherosclerotic cardiovascular disease; CKD: chronic kidney disease; HF: heart failure; MASLD: metabolic dysfunction-associated steatotic liver disease. 4. Residual Cardiometabolic Risk: What HbA1c Does Not Capture Even when glycaemic targets are met, a substantial burden of risk often remains. This residual cardiometabolic risk is driven by factors that HbA1c simply does not measure: persistent albuminuria, visceral adiposity, atherogenic dyslipidaemia, subclinical heart failure and ongoing kidney decline. Recognising it has reframed the therapeutic goal from normalising a single number to protecting the organs most likely to fail. The DAPA-HF trial, for example, showed that dapagliflozin reduced worsening heart failure and cardiovascular death even in patients without diabetes [7], while FLOW demonstrated that semaglutide slowed kidney disease progression in patients with diabetes and chronic kidney disease [8]. The benefit, in these settings, is no longer about glucose at all. 5. The Next Frontier: Integrated Cardiometabolic Risk Future diabetes care will depend on integrating multiple clinical domains into a single decision-making framework. Digital health technologies, artificial intelligence, continuous glucose monitoring and electronic health records may help clinicians identify high-risk phenotypes and select personalised strategies, flagging, for instance, the patient whose declining estimated glomerular filtration rate and rising albuminuria warrant earlier organ protection. Used well, such systems could shorten the gap between a worsening trajectory and the moment a protective therapy is actually started. These tools are not intended to replace clinical judgement, but to enhance it through more efficient interpretation of increasingly complex information. The challenge will be to transform data into decisions that are clinically meaningful, feasible and centred on the individual patient [8–10]. 6. Looking Beyond HbA1c The success of modern diabetes care should no longer be measured exclusively by lower HbA1c values. Preserving kidney function, reducing cardiovascular events, preventing heart failure, improving metabolic health and addressing obesity have become equally important therapeutic objectives. The evidence now extends beyond diabetes itself: in SELECT, semaglutide reduced cardiovascular events in people with obesity but without diabetes, underlining how far the field has moved from a purely glucose-centred view [9]. Precision medicine is therefore not a distant aspiration, but the natural evolution of evidence-based diabetes care. As therapies continue to expand and risk assessment becomes more sophisticated, clinicians will be increasingly able to deliver personalised cardiometabolic care focused on the outcomes that matter most to patients. References American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes—2025. Diabetes Care. 2025, 48, S1–S350. Davies, M.J.; Aroda, V.R.; Collins, B.S.; Gabbay, R.A.; Green, J.; Maruthur, N.M.; Rosas, S.E.; Del Prato, S.; et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetologia. 2022, 65, 1925–1966. Marx, N.; Federici, M.; Schütt, K.; Müller-Wieland, D.; Ajjan, R.A.; Antunes, M.J.; Christodorescu, R.M.; Crawford, C.; et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur. Heart J. 2023, 44, 4043–4140. Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015, 373, 2117–2128. Marso, S.P.; Daniels, G.H.; Brown-Frandsen, K.; Kristensen, P.; Mann, J.F.E.; Nauck, M.A.; Nissen, S.E.; Pocock, S.; et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2016, 375, 311–322. Marso, S.P.; Bain, S.C.; Consoli, A.; Eliaschewitz, F.G.; Jodár, E.; Leiter, L.A.; Lingvay, I.; Rosenstock, J.; et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2016, 375, 1834–1844. McMurray, J.J.V.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Sabatine, M.S.; et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N. Engl. J. Med. 2019, 381, 1995–2008. Perkovic, V.; Tuttle, K.R.; Rossing, P.; Mahaffey, K.W.; Mann, J.F.E.; Bakris, G.; Baeres, F.M.M.; Idorn, T.; et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 2024, 391, 109–121. Lincoff, A.M.; Brown-Frandsen, K.; Colhoun, H.M.; Deanfield, J.; Emerson, S.S.; Esbjerg, S.; Hardt-Lindberg, S.; Hovingh, G.K.; et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N. Engl. J. Med. 2023, 389, 2221–2232. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022, 102, S1–S127. Biography Antonio Maria Labate, MD, is a specialist in Internal Medicine working as an outpatient diabetology and internal medicine specialist at ASST Franciacorta and ASST Mantova, in Lombardy, Italy. He trained in Internal Medicine at the University of Messina and has broad clinical experience spanning internal medicine, emergency medicine and diabetology. His work focuses on clinical diabetology, cardiovascular and cardiometabolic risk in type 2 diabetes, real-world evidence, and the clinical use of newer glucose-lowering therapies such as GLP-1 receptor agonists and SGLT2 inhibitors. He has authored peer-reviewed articles and congress communications on the cardiovascular, renal and metabolic effects of these agents, and serves as a reviewer for several international journals.
Blog 08 Jul 2026
The Encyclopedia platform, together with the journals Biology and Nutrients, launches the Best Video Abstract Awards to increase the visibility and reach of published research and to inspire researchers to explore the power of visual storytelling. Video abstracts have become an increasingly important medium for scientific communication. By integrating narration, visualizations, animations, and experimental footage, they make complex research more accessible, engaging, and memorable. This initiative recognizes video abstracts that are not only scientifically rigorous but also creatively compelling and educational, thereby promoting broader dissemination and deeper community engagement. To learn more about the awards or to participate directly, please visit the event page via the links provided below. https://encyclopedia.pub/best-video-abstract-award 1. Event Duration 9 February 2026 – 2 February 2027 2. Awards Biology Best Video Abstract AwardOpen to video abstracts based on papers published in Biology between 1 January 2024 and 31 December 2025. This award will be granted to two video abstracts based on the evaluation of the Award Evaluation Committee. Nutrients Best Video Abstract AwardOpen to video abstracts based on papers published in Nutrients between 1 January 2024 and 31 December 2025. This award will be granted to two video abstracts based on the evaluation of the Award Evaluation Committee. Prize For each journal award, the winner will receive: CHF 500 A voucher waiving the Article Processing Charges (APCs) for one journal submission (subject to peer review, valid for one year) A free Academic Video Service production (no matter where the paper is published), valid for one year. An electronic certificate Participant Incentive All participants will receive a CHF 100 discount voucher for the Encyclopedia Academic Video Service. 3. Participation The event will be conducted in three stages. Submission Stage 9 February 2026 – 31 August 2026 Independent Submission Authors may create and submit video abstracts independently using their own tools and creative approach. Professional Support Option Authors who do not currently have a video abstract but intend to apply for the award may opt for the Academic Video Service, which offers a one-stop, end-to-end solution covering script development, animation, voiceover recording, and editing. Please submit your video abstract here: https://encyclopedia.pub/user/video_add?activity=b57ab0910b456a5e4eebd960867ce205 Or place your video service order here: https://encyclopedia.pub/user/video_service_order All video abstracts will be assessed by the editorial team for editorial suitability and overall quality. Submissions that meet the guidelines will be assessed equally. Voting Stage 1 November 2026 – 31 December 2026 Public voting will be conducted during this period. Voting results and video performance metrics, including views, likes, shares, and collections, will contribute to the final evaluation. Winner Announcement 2 February 2027 Final winners will be determined based on a combined assessment of public voting results and a comprehensive evaluation by the Award Evaluation Committee, which carries the primary weight in the final decision. Winners will be announced on the Encyclopedia platform and journal websites. 4. Others If you have any other questions, please contact office@encyclopedia.pub
Announcement 09 Feb 2026
Journal Encyclopedia
More  >>
See what people are saying about us
Shlomi Agmon
Encyclopedia Video provides potential readers with a tool to quickly understand what the work is about. That is important for casualreaders, whose time is thus spared, and for investedreaders, for whom it makes the decision to say "yes, I want to read the paper" much simpler.
School of Computer Science and Engineering, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel
Ignacio Cea
For the video abstracts, the papers and authors could gain more visibility and increase citations. Also, it means a more diverse and interesting way of communicating research, which is something valuable in itself.
Center for Research, Innovation and Creation, and Faculty of Religious Sciences and Philosophy, Temuco Catholic University
Melvin R. Pete Hayden
Thank the video production crew for making such a wonderful video. The narrations have been significantly added to the video! Congratulations on such an outstanding job of Encyclopedia Video team.
University of Missouri School of Medicine, United States
Academic Video Service